Klebsiella ESBL bacteremia-mortality and risk factors.

[1]  R. Rehmani,et al.  Extended spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae bacteremia. Risk factors and outcome in the eastern region of Saudi Arabia. , 2009, Saudi medical journal.

[2]  P. Chiusolo,et al.  Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. , 2009, The Journal of infection.

[3]  A. Levin,et al.  Trends and outcome of 1121 nosocomial bloodstream infections in intensive care units in a Brazilian hospital, 1999-2003. , 2008, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[4]  Clinical,et al.  Performance Standards for Antimicrobial Susceptibility Testing; Eighteenth Informational Supplement , 2008 .

[5]  M. Kolář,et al.  Influence of third‐generation cephalosporin utilization on the occurrence of ESBL‐positive Klebsiella pneumoniae strains , 2007, Journal of clinical pharmacy and therapeutics.

[6]  W. Bilker,et al.  Impact of Different Methods for Describing the Extent of Prior Antibiotic Exposure on the Association Between Antibiotic Use and Antibiotic-Resistant Infection , 2007, Infection Control & Hospital Epidemiology.

[7]  F. Baquero,et al.  In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). , 2006, The Journal of antimicrobial chemotherapy.

[8]  J. Vila,et al.  Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases. , 2006, The Journal of antimicrobial chemotherapy.

[9]  A. Marra,et al.  Nosocomial bloodstream infections caused by Klebsiella pneumoniae: impact of extended-spectrum β-lactamase (ESBL) production on clinical outcome in a hospital with high ESBL prevalence , 2006, BMC infectious diseases.

[10]  A. Marra,et al.  Health and economic outcomes of the detection of Klebsiella pneumoniae-produced extended-spectrum beta-lactamase (ESBL) in a hospital with high prevalence of this infection. , 2006, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[11]  A. Hsiung,et al.  Antimicrobial susceptibility of Gram-negative bacteria in Brazilian hospitals: the MYSTIC Program Brazil 2003. , 2005, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

[12]  H. Goossens,et al.  Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  H. Goossens,et al.  International Prospective Study of Klebsiella pneumoniae Bacteremia: Implications of Extended-Spectrum -Lactamase Production in Nosocomial Infections , 2004, Annals of Internal Medicine.

[14]  Ronald N. Jones,et al.  Four-year evaluation of frequency of occurrence and antimicrobial susceptibility patterns of bacteria from bloodstream infections in Latin American medical centers. , 2002, Diagnostic microbiology and infectious disease.

[15]  Dechang Chen,et al.  Extended-spectrum beta-lactamase-producing Escherichiacoli and Klebsiellapneumoniae bloodstream infection: risk factors and clinical outcome , 2002, Intensive Care Medicine.

[16]  K. Riesenberg,et al.  Clinical significance and impact on mortality of extended-spectrum beta lactamase-producing Enterobacteriaceae isolates in nosocomial bacteremia. , 2001, Scandinavian journal of infectious diseases.